Huizhe Wu

7.5k total citations
60 papers, 1.7k citations indexed

About

Huizhe Wu is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Huizhe Wu has authored 60 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Molecular Biology, 24 papers in Cancer Research and 18 papers in Oncology. Recurrent topics in Huizhe Wu's work include Cancer-related molecular mechanisms research (17 papers), RNA modifications and cancer (16 papers) and MicroRNA in disease regulation (8 papers). Huizhe Wu is often cited by papers focused on Cancer-related molecular mechanisms research (17 papers), RNA modifications and cancer (16 papers) and MicroRNA in disease regulation (8 papers). Huizhe Wu collaborates with scholars based in China, Saint Kitts and Nevis and United States. Huizhe Wu's co-authors include Minjie Wei, Weifan Yao, Miao He, Xiao Hu, Qinghuan Xiao, Zhaojin Yu, Haishan Zhao, Lin Zhao, Qiuchen Chen and Yalun Li and has published in prestigious journals such as Blood, PLoS ONE and Oncogene.

In The Last Decade

Huizhe Wu

55 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Huizhe Wu China	24	1.3k	803	426	143	92	60	1.7k
Yue Gong China	17	736 0.6×	628 0.8×	554 1.3×	396 2.8×	83 0.9×	47	1.6k
Toshiyuki Tsunoda Japan	23	843 0.7×	333 0.4×	328 0.8×	160 1.1×	61 0.7×	77	1.3k
Weigang Fang China	28	1.1k 0.9×	484 0.6×	433 1.0×	249 1.7×	173 1.9×	80	2.1k
Andrea Sacconi Italy	31	1.8k 1.4×	1.3k 1.6×	463 1.1×	207 1.4×	192 2.1×	95	2.5k
Angélica Figueroa Spain	25	1.2k 0.9×	559 0.7×	439 1.0×	146 1.0×	89 1.0×	46	1.7k
Zihuan Yang China	21	678 0.5×	321 0.4×	272 0.6×	130 0.9×	97 1.1×	57	1.1k
Yanjun Mi China	19	631 0.5×	381 0.5×	235 0.6×	294 2.1×	37 0.4×	39	1.1k
Shuai Zhu China	18	998 0.8×	832 1.0×	208 0.5×	59 0.4×	83 0.9×	29	1.3k
Hui Xing China	22	768 0.6×	387 0.5×	343 0.8×	100 0.7×	59 0.6×	54	1.2k

Countries citing papers authored by Huizhe Wu

Since Specialization

Citations

This map shows the geographic impact of Huizhe Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Huizhe Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Huizhe Wu more than expected).

Fields of papers citing papers by Huizhe Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Huizhe Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Huizhe Wu. The network helps show where Huizhe Wu may publish in the future.

Co-authorship network of co-authors of Huizhe Wu

This figure shows the co-authorship network connecting the top 25 collaborators of Huizhe Wu. A scholar is included among the top collaborators of Huizhe Wu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Huizhe Wu. Huizhe Wu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wu, Ting, Ying‐Qi Zhao, Xinming Zhang, et al.. (2025). Short‐chain acyl post‐translational modifications in cancers: Mechanisms, roles, and therapeutic implications. Cancer Communications. 45(10). 1247–1284. 17 indexed citations

Geng, Ren, Jianhua Miao, Yi Qin, et al.. (2024). MA15.13 Furmonertinib as Adjuvant Therapy for Completely Resected Stage IA with High-Risk Factors and IB NSCLC Patients with EGFR Mutations. Journal of Thoracic Oncology. 19(10). S120–S121.

Zhou, Heng, et al.. (2024). Distinctive tumorigenic significance and innovative oncology targets of SUMOylation. Theranostics. 14(8). 3127–3149. 5 indexed citations

Hu, Xiao, Min Liu, Ming‐Rong Zhang, et al.. (2024). SnoRNAs: The promising targets for anti-tumor therapy. Journal of Pharmaceutical Analysis. 14(11). 101064–101064. 4 indexed citations

Yan, Yuanyuan, Miao He, Lin Zhao, et al.. (2022). A novel HIF-2α targeted inhibitor suppresses hypoxia-induced breast cancer stemness via SOD2-mtROS-PDI/GPR78-UPRER axis. Cell Death and Differentiation. 29(9). 1769–1789. 63 indexed citations

Li, Yalun, Huizhe Wu, Chengzhong Xing, et al.. (2020). Prognostic evaluation of colorectal cancer using three new comprehensive indexes related to infection, anemia and coagulation derived from peripheral blood. Journal of Cancer. 11(13). 3834–3845. 23 indexed citations

Wang, Xiufang, Zhikun Wu, Wenyan Qin, et al.. (2020). Long non-coding RNA ZFAS1 promotes colorectal cancer tumorigenesis and development through DDX21-POLR1B regulatory axis. Aging. 12(22). 22656–22687. 26 indexed citations

Sun, Tong, Zhikun Wu, Xiufang Wang, et al.. (2020). LNC942 promoting METTL14-mediated m6A methylation in breast cancer cell proliferation and progression. Oncogene. 39(31). 5358–5372. 154 indexed citations

Chen, Qiuchen, Xiaolan Deng, Xiao Hu, et al.. (2019). Breast Cancer Risk–Associated SNPs in the mTOR Promoter Form De Novo KLF5- and ZEB1-Binding Sites that Influence the Cellular Response to Paclitaxel. Molecular Cancer Research. 17(11). 2244–2256. 10 indexed citations

10.

He, Miao, Huizhe Wu, Qian Jiang, et al.. (2018). Hypoxia‐inducible factor‐2α directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycin. Molecular Oncology. 13(2). 403–421. 49 indexed citations

11.

Hu, Xiao, Wenyan Qin, Miao He, et al.. (2018). Polymorphisms in DNA repair pathway genes and <em>ABCG2</em> gene in advanced colorectal cancer: correlation with tumor characteristics and clinical outcome in oxaliplatin-based chemotherapy. Cancer Management and Research. Volume 11. 285–297. 12 indexed citations

12.

Weng, Hengyou, Huilin Huang, Huizhe Wu, et al.. (2018). N6-Methyladenosine Modification Regulates Cell Metabolism in Acute Myeloid Leukemia. Blood. 132(Supplement 1). 880–880.

13.

Zhang, Zhen, Qiuchen Chen, Jing Zhang, et al.. (2017). Associations of genetic polymorphisms in pTEN/AKT/mTOR signaling pathway genes with cancer risk: A meta-analysis in Asian population. Scientific Reports. 7(1). 17844–17844. 16 indexed citations

14.

Zhao, Haishan, Zhaojin Yu, Lin Zhao, et al.. (2016). HDAC2 overexpression is a poor prognostic factor of breast cancer patients with increased multidrug resistance-associated protein expression who received anthracyclines therapy. Japanese Journal of Clinical Oncology. 46(10). 893–902. 36 indexed citations

15.

Zhao, Haishan, Qinghuan Xiao, Miao He, et al.. (2016). The Hedgehog signaling pathway is associated with poor prognosis in breast cancer patients with the CD44+/CD24− phenotype. Molecular Medicine Reports. 14(6). 5261–5270. 20 indexed citations

16.

Wu, Huizhe, Shu Guan, Mingli Sun, et al.. (2015). Ano1/TMEM16A Overexpression Is Associated with Good Prognosis in PR-Positive or HER2-Negative Breast Cancer Patients following Tamoxifen Treatment. PLoS ONE. 10(5). e0126128–e0126128. 36 indexed citations

17.

He, Miao, Yuanyuan Yan, Qinghuan Xiao, et al.. (2015). The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients. Clinical Science. 129(9). 809–822. 49 indexed citations

18.

Yu, Zhaojin, Mingli Sun, Feng Jin, et al.. (2015). Combined expression of ezrin and E-cadherin is associated with lymph node metastasis and poor prognosis in breast cancer. Oncology Reports. 34(1). 165–174. 21 indexed citations

19.

Jiang, Qian, Miao He, Shu Guan, et al.. (2015). MicroRNA-100 suppresses the migration and invasion of breast cancer cells by targeting FZD-8 and inhibiting Wnt/β-catenin signaling pathway. Tumor Biology. 37(4). 5001–5011. 77 indexed citations

20.

Ma, Mengtao, Miao He, Yan Wang, et al.. (2013). MiR-487a resensitizes mitoxantrone (MX)-resistant breast cancer cells (MCF-7/MX) to MX by targeting breast cancer resistance protein (BCRP/ABCG2). Cancer Letters. 339(1). 107–115. 89 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact